Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Macroflux Corp.

This article was originally published in Start Up

Executive Summary

These days, many start-ups aim to improve upon existing drugs, and swipe some of their market share, by dint of novel delivery methods. Macroflux has those aspirations, and considerably more means to realize them than most firms founded just six months ago. The company is a spin-out from J&J's Alza Corp., one of the most productive drug delivery outfits ever. Macroflux will commercialize a patch-based drug delivery system that the company expects will be a virtually painless way to deliver therapeutic proteins, peptides, and vaccines.

You may also be interested in...



Drug Delivery Companies Hop On the Transdermal Express

Transdermal drug delivery has come a long way since the first patch for seasickness. In a drug delivery device industry on track to reach almost $23 billion by the year 2011 (according to "US Markets for Drug and Fluid Delivery Devices," published in October 2007 by Windhover Information's Medtech Insight division) the transdermal sector will grow at a faster rate than injection or inhalation drug delivery systems. Transdermal delivery technologies will grow at a compound annual rate of more than 11% over the next four years, building up to sales of $3.5 billion in the year 2011.

Corporate VC Adds a Business Development Flavor

Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.

Corporate VC Adds a Business Development Flavor

Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091390

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel